Achieving Flexibility And Scalability In Cell Therapy Manufacturing Through Optimized Cell Isolation And Activation

Learn about a first-of-its-kind platform technology that enables isolation and activation of T cells in one step with a key differentiator: an active release mechanism for clinical trial or commercial manufacturing. The Gibco™ CTS™ Detachable Dynabeads™ CD3/CD28 Kit possesses a proprietary active release mechanism that enables the intentional early release of Dynabeads from the cells before the naturally occurring release at day 4 or 5. Conjugated to highly specific, single-domain VHH antibodies that target specific clusters of differentiation markers, the performance exhibits consistent and optimal isolation, activation, and purity of target T cell populations while addressing the biological variability that cell therapy manufacturers are facing.

In this webinar you will learn about:

• How the active detachment of Dynabeads from target cells at any time allows users to add flexibility and scalability to their process
• How to maintain desired cell phenotypes
• Suitability for both autologous and allogeneic processes